{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:14:30Z","timestamp":1761581670356,"version":"3.44.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ucl.2017.12.002","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T03:35:19Z","timestamp":1519184119000},"page":"155-167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma"],"prefix":"10.1016","volume":"45","author":[{"given":"William","family":"Tabayoyong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib1","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.eururo.2008.10.016","article-title":"Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer","volume":"55","author":"Calabro","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib3","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib4","first-page":"486","article-title":"Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era","volume":"176","author":"Hautmann","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11864-015-0376-y","article-title":"Chemotherapy for muscle-invasive bladder cancer","volume":"17","author":"Trenta","year":"2016","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2017.12.002_bib6","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.urolonc.2012.01.012","article-title":"Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting","volume":"30","author":"Apolo","year":"2012","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib7","first-page":"451","article-title":"Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base","volume":"178","author":"David","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.urology.2013.07.072","article-title":"Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database","volume":"83","author":"Zaid","year":"2014","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib9","first-page":"110","article-title":"An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma","volume":"169","author":"Sanchez-Ortiz","year":"2003","journal-title":"J\u00a0Urol"},{"issue":"4 Pt 1","key":"10.1016\/j.ucl.2017.12.002_bib10","first-page":"1085","article-title":"Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage","volume":"170","author":"Chang","year":"2003","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.hoc.2014.10.011","article-title":"Nonurothelial bladder cancer and rare variant histologies","volume":"29","author":"Willis","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"issue":"20","key":"10.1016\/j.ucl.2017.12.002_bib12","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/JCO.2001.19.20.4005","article-title":"Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC","volume":"19","author":"Millikan","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2017.12.002_bib13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/j.1464-410X.1991.tb15225.x","article-title":"Neo-adjuvant\u00a0(pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder","volume":"67","author":"Wallace","year":"1991","journal-title":"Br J Urol"},{"issue":"3 Pt 2","key":"10.1016\/j.ucl.2017.12.002_bib14","first-page":"964","article-title":"Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study","volume":"153","author":"Martinez-Pineiro","year":"1995","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2017.12.002_bib15","first-page":"1903","article-title":"Five-year\u00a0followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group","volume":"155","author":"Malmstrom","year":"1996","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2003.09.019","article-title":"Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies","volume":"45","author":"Sherif","year":"2004","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2017.12.002_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/003655902762467567","article-title":"Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer: Nordic Cystectomy Trial 2","volume":"36","author":"Sherif","year":"2002","journal-title":"Scand J Urol Nephrol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"issue":"9178","key":"10.1016\/j.ucl.2017.12.002_bib19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(99)02292-8","article-title":"Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists","volume":"354","year":"1999","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ucl.2017.12.002_bib20","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ucl.2017.12.002_bib21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.ucl.2017.12.002_bib22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A\u00a0randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.ucl.2017.12.002_bib23","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity","volume":"32","author":"Plimack","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.ucl.2017.12.002_bib24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2013.52.4785","article-title":"Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates","volume":"32","author":"Choueiri","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ucl.2017.12.002_bib25","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.ucl.2017.12.002_bib26","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.urology.2011.10.050","article-title":"Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder","volume":"79","author":"Yeshchina","year":"2012","journal-title":"Urology"},{"issue":"15","key":"10.1016\/j.ucl.2017.12.002_bib28","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/cncr.29387","article-title":"Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer","volume":"121","author":"Galsky","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A\u00a0consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2017.12.002_bib30","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/(SICI)1097-0142(19971115)80:10<1966::AID-CNCR14>3.0.CO;2-W","article-title":"Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma","volume":"80","author":"Bellmunt","year":"1997","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<344::AID-CNCR18>3.0.CO;2-1","article-title":"Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study","volume":"77","author":"Petrioli","year":"1996","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib32","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.eururo.2006.12.029","article-title":"Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial","volume":"52","author":"Dogliotti","year":"2007","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib33","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/cncr.27751","article-title":"A\u00a0phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results","volume":"119","author":"Siefker-Radtke","year":"2013","journal-title":"Cancer"},{"issue":"10064","key":"10.1016\/j.ucl.2017.12.002_bib34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib35","first-page":"552","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J\u00a0Urol"},{"issue":"12","key":"10.1016\/j.ucl.2017.12.002_bib36","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1586\/era.09.146","article-title":"Surgical consolidation of initially unresectable urothelial carcinoma: an incremental opportunity to cure","volume":"9","author":"Siefker-Radtke","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib37","first-page":"53","article-title":"A\u00a0multi-institutional analysis of outcomes of patients with clinically node positive urothelial bladder cancer treated with induction chemotherapy and radical cystectomy","volume":"195","author":"Zargar-Shoshtari","year":"2016","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib38","doi-asserted-by":"crossref","first-page":"59.e1-8","DOI":"10.1016\/j.urolonc.2015.08.012","article-title":"Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: the M.D. Anderson cancer center experience","volume":"34","author":"Ho","year":"2016","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib39","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urology.2013.08.082","article-title":"Induction chemotherapy followed by surgery in node positive bladder cancer","volume":"83","author":"Meijer","year":"2014","journal-title":"Urology"},{"issue":"22","key":"10.1016\/j.ucl.2017.12.002_bib40","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.2016.67.5033","article-title":"Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement","volume":"34","author":"Galsky","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2017.12.002_bib41","first-page":"2476","article-title":"A\u00a0sequential treatment approach to myoinvasive urothelial cancer: a phase II southwest oncology group trial (S0219)","volume":"181","author":"White","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib42","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eururo.2007.12.031","article-title":"Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib43","first-page":"619","article-title":"Long-term\u00a0renal function outcomes after radical cystectomy","volume":"191","author":"Eisenberg","year":"2014","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib44","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/cncr.22031","article-title":"Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder","volume":"107","author":"Dash","year":"2006","journal-title":"Cancer"},{"issue":"5b","key":"10.1016\/j.ucl.2017.12.002_bib45","doi-asserted-by":"crossref","first-page":"E17","DOI":"10.1111\/bju.12274","article-title":"Eligibility for neoadjuvant\/adjuvant cisplatin-based chemotherapy among radical cystectomy patients","volume":"113","author":"Thompson","year":"2014","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib46","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","article-title":"Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience","volume":"55","author":"Donat","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib47","first-page":"459","article-title":"The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial","volume":"145","author":"Skinner","year":"1991","journal-title":"J\u00a0Urol"},{"issue":"2 Pt 1","key":"10.1016\/j.ucl.2017.12.002_bib48","first-page":"302","article-title":"Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study","volume":"148","author":"Stockle","year":"1992","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib49","first-page":"47","article-title":"Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience","volume":"153","author":"Stockle","year":"1995","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib50","first-page":"81","article-title":"Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial","volume":"152","author":"Studer","year":"1994","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib51","first-page":"495","article-title":"A\u00a0randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer","volume":"155","author":"Freiha","year":"1996","journal-title":"J\u00a0Urol"},{"issue":"7","key":"10.1016\/j.ucl.2017.12.002_bib52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1023\/A:1008399130226","article-title":"The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why","volume":"11","author":"Sylvester","year":"2000","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eururo.2005.04.005","article-title":"Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib54","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/annonc\/mdr354","article-title":"Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial","volume":"23","author":"Cognetti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2017.12.002_bib55","doi-asserted-by":"crossref","first-page":"18s","DOI":"10.1200\/jco.2010.28.18_suppl.lba4518","article-title":"Randomized phase III trial comparing adjuvant paclitaxel\/gemcitabine\/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of\u00a0the Spanish Oncology Genitourinary Group (SOGUG) 99\/01 study","volume":"28","author":"Paz-Ares","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib57","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2017.12.002_bib58","doi-asserted-by":"crossref","first-page":"e000126","DOI":"10.1136\/esmoopen-2016-000126","article-title":"Upper tract urothelial carcinoma: a different disease entity in terms of management","volume":"1","author":"Leow","year":"2016","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.ucl.2017.12.002_bib59","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urolonc.2010.07.016","article-title":"The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC)","volume":"31","author":"Audenet","year":"2013","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib60","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urology.2007.03.051","article-title":"Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy","volume":"70","author":"Brown","year":"2007","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib61","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000282755","article-title":"Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract","volume":"55","author":"Igawa","year":"1995","journal-title":"Urol Int"},{"issue":"12","key":"10.1016\/j.ucl.2017.12.002_bib62","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2017.12.002_bib63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/iju.13010","article-title":"Effect of preoperative chemotherapy on survival of patients with upper urinary tract urothelial carcinoma clinically involving regional lymph nodes","volume":"23","author":"Kobayashi","year":"2016","journal-title":"Int J Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.12.002_bib64","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","article-title":"A\u00a0systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.12.002_bib65","first-page":"40","article-title":"Refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"191","author":"Culp","year":"2014","journal-title":"J\u00a0Urol"},{"issue":"8","key":"10.1016\/j.ucl.2017.12.002_bib66","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.urolonc.2013.10.021","article-title":"Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum","volume":"32","author":"Dinney","year":"2014","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2017.12.002_bib67","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014317301441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014317301441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:36:43Z","timestamp":1758807403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014317301441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":67,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0094014317301441"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2017.12.002","relation":{},"ISSN":["0094-0143"],"issn-type":[{"type":"print","value":"0094-0143"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2017.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}